Day 4

Sunday, August 18th


    We are in the midst of a massive expansion in clinical research and cultural awareness of the benefits of psychedelic medicines, and in many ways, these are the most powerful tools for transformation of modern-day psycho-emotional suffering. In this talk, Dr. Engle will discuss the most often used current medicines for healing through shifting consciousness, their relevant data for support, the right use, practices for positive outcomes, and where this exciting field has the potential to go.

  • Re-Purposing Psychiatry in the 21st Century: The Challenges of Essential Medical Care and Responsible Prescribing

    The practice of psychiatry in the 21st century faces new challenges, involving the essential medical care of patients and embracing a comprehensive understanding of expanded uses and long-term toxicities of psychiatric drugs. The purpose of this presentation is to empower psychiatrists to step forward into roles which challenge the past millennium's paradigm of care. It is time for clinicians to boldly accept responsibility for the unmet medical needs of psychiatric patients, and to prescribe (or de-prescribe) psychotropic drugs conscientiously. This presentation draws from epidemiological studies, case reports, basic science research, and from Dr. Jackson’s direct experience in patient care.

  • Neuropsychiatric Lyme Disease and Associated Co-Infections: Clinical Presentations, Diagnostic Challenges, and Treatment Options

    Lyme Disease and other tick-borne illnesses have risen exponentially in recent years, yet their symptoms are not well known, and can mimic nearly any psychiatric condition. In this presentation, Dr. Chandra will address the challenges and complexities in diagnosing these conditions and will also discuss integrative approaches to treatment.

  • New Frontiers in Mental Health: CBD and Beyond

    This presentation will explore several innovations in mental health. First, Dr. Shannon will provide some background on cannabidiol (CBD) and then present his research on this agent in psychiatry. Then as one of the 12 international site Principle Investigators for the current Phase III study of MDMA (MDMA was just awarded Breakthrough Therapy designation by the FDA), Dr. Shannon will give some history about this agent, the current study, and the implications for the field of mental health. He will then cover a few other exciting new developments in mental health and present some cases with practical guidance.

  • The Integrative Treatment of ADHD

    Drawing from his experience as the head of the Pediatric Integrative Neurodevelopmental Program at the Osher Center, specializing in the treatment of autism, ADHD, and other developmental childhood conditions, Dr. Newmark’s presentation will discuss the dramatic increase of the diagnosis of ADHD, form an integrative perspective, as well as discuss a wide range of evidence-based integrative treatments that may be helpful, whether or not pharmaceutical interventions are employed.

  • Bioidentical Hormone Replacement Therapy for Mood and Cognition

    In this presentation, Dr. Hathaway will discuss the literature and controversy surrounding BHRT for postmenopausal women, regarding both potential cognitive protection and impact on mood. She will also review known mechanisms of action of both the protective effects and mood enhancement using specific illustrative cases.

  • Non-Pharmacological Treatments for Chronic Pain: What Mental Health Practitioners Need to Know

    We are seeing a swift pendulum swing regarding opioid prescribing for people who suffer from chronic pain (CP). This shift has provided a valuable opportunity for pain psychologists to assist with education and treatment. This presentation will provide an overview on empirically validated psychological and behavioral treatments for chronic pain.

  • End of Conference